MilliporeSigma
Sigma-Aldrich Licenses CRISPR-Cas9 Tech to Horizon Discovery
The deal enables Horizon to support gene editing researchers who need cell-line engineering beyond loss-of-function CRISPR studies into CRISPR-mediated targeted knock-in.
MilliporeSigma Licenses Sigma-Aldrich CRISPR IP to Agbio Firm BetterSeeds
MilliporeSigma said that BetterSeeds will use the intellectual property to improve traits in cash crops such as cannabis and cowpea.
MilliporeSigma Licenses CRISPR-Cas9 Technology to Cellecta
Cellecta said it will use MilliporeSigma's technology to offer its customers CRISPR-mediated targeted gene knock-in services.
Mammoth Biosciences, Agilent to Comarket CRISPR-Based SARS-CoV-2 Test
The diagnostic is composed of Agilent's Bravo automation workstation and Mammoth's DETECTR BOOST SARS-CoV-2 assay.
Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test With MilliporeSigma, Hamilton Company
The CRISPR-based test uses Mammoth's DETECTR BOOST platform and will be compatible with both nasal swab and saliva samples.
Dec 19, 2019
MilliporeSigma Licenses CRISPR Tech to Promega
Apr 11, 2017
May 19, 2016
Nov 18, 2015
Merck KGaA Completes $17B Sigma-Aldrich Acquisition
Oct 29, 2015
Sigma-Aldrich Acquiring Olink's Duolink Line
Aug 11, 2015